Harvard Historical Cash Flow
| HBIO Stock | USD 2.20 0.01 0.46% |
Analysis of Harvard Bioscience cash flow over time is an excellent tool to project Harvard Bioscience future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 1.6 M or End Period Cash Flow of 4.1 M as it is a great indicator of Harvard Bioscience ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Harvard Bioscience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Harvard Bioscience is a good buy for the upcoming year.
Harvard |
About Harvard Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Harvard balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Harvard's non-liquid assets can be easily converted into cash.
Harvard Bioscience Cash Flow Chart
Add Fundamental
Depreciation
Depreciation indicates how much of Harvard Bioscience value has been used up. For tax purposes Harvard Bioscience can deduct the cost of the tangible assets it purchases as business expenses. However, Harvard Bioscience must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Exchange Rate Changes
The impact of changes in foreign exchange rates on a company's financial position and results.Most accounts from Harvard Bioscience's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Harvard Bioscience current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.At this time, Harvard Bioscience's Change To Account Receivables is very stable compared to the past year. As of the 29th of November 2024, Change Receivables is likely to grow to about 5.8 M, while Depreciation is likely to drop about 4.9 M.
Harvard Bioscience cash flow statement Correlations
Click cells to compare fundamentals
Harvard Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Harvard Bioscience cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation | 7.7M | 7.6M | 7.6M | 7.6M | 7.0M | 4.9M | |
| Other Non Cash Items | 2.3M | 1.9M | 280K | (3.6M) | 509K | 534.5K | |
| Capital Expenditures | 1.2M | 1.2M | 1.3M | 1.6M | 2.3M | 1.6M | |
| Net Income | (4.7M) | (7.8M) | (288K) | (9.5M) | (3.4M) | (3.6M) | |
| End Period Cash Flow | 8.3M | 8.3M | 7.8M | 4.5M | 4.3M | 4.1M | |
| Change To Inventory | 3.3M | 413K | (5.9M) | 252K | 1.5M | 1.6M | |
| Change In Cash | 162K | (18K) | (496K) | (3.3M) | (225K) | (213.8K) | |
| Free Cash Flow | 6.8M | 8.2M | (83K) | (438K) | 11.7M | 12.3M | |
| Change In Working Capital | 42K | 4.1M | (10.2M) | 2.7M | 4.6M | 4.8M | |
| Begin Period Cash Flow | 8.2M | 8.3M | 8.3M | 7.8M | 4.5M | 4.3M | |
| Other Cashflows From Financing Activities | 4.7M | 70K | (302K) | 577K | (2.5M) | (2.4M) | |
| Total Cash From Operating Activities | 8.0M | 9.3M | 1.3M | 1.2M | 14.0M | 14.7M | |
| Total Cash From Financing Activities | (7.6M) | (8.0M) | (252K) | (2.8M) | (12.1M) | (11.5M) | |
| Sale Purchase Of Stock | (221K) | (1.1M) | (3.5M) | (1.6M) | (2.5M) | (2.4M) | |
| Change To Liabilities | (4.0M) | 479K | (101K) | (1.9M) | (1.7M) | (1.7M) | |
| Stock Based Compensation | 3.0M | 3.6M | 4.2M | 4.4M | 5M | 4.8M | |
| Change To Account Receivables | 468K | 3.1M | (4.3M) | 4.8M | 810K | 850.5K | |
| Change To Netincome | 5.0M | 5.2M | 4.2M | 4.4M | 5.1M | 3.4M | |
| Other Cashflows From Investing Activities | (52.8M) | 987K | (250K) | (150K) | (135K) | (141.8K) | |
| Change Receivables | 468K | 3.1M | (4.3M) | 4.8M | 5.5M | 5.8M | |
| Net Borrowings | (7.4M) | (7.5M) | (52K) | (1.8M) | (2.1M) | (2.0M) | |
| Total Cashflows From Investing Activities | (229K) | (1.4M) | (1.3M) | (1.6M) | (1.8M) | (1.9M) | |
| Cash And Cash Equivalents Changes | 192K | (38K) | (335K) | (3.3M) | (3.8M) | (3.6M) | |
| Cash Flows Other Operating | 5.6M | 5.7M | 5.6M | 1.4M | 1.6M | 2.1M | |
| Change To Operating Activities | (1.4M) | 4.1M | (10.2M) | (66K) | (59.4K) | (62.4K) | |
| Investments | (229K) | (1.4M) | (1.3M) | (1.6M) | (973K) | (1.0M) |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.